Background: We need population-specific clinical features that can predict bone metastases as an affordable therapeutic decision-making tool in newly diagnosed prostate cancer patients as scintigraphy or positron emission tomography are not available and as no such study had ever been performed in our country. Objective: To determine biologic and pathologic criteria that can predict the scintigraphic detection of bone metastases in our prostate cancer patients. Patients and Method: We analyzed with student’s t test and logistic regression the PSA level, the ISUP grade and the scintigraphic data retrospectively collected in newly diagnosed prostate cancer patients. Results: In ten years, 36 prostate cancer patients were sent to the Korle Bu Teaching Hospital in Accra (Ghana) for bone scintigraphy (mean age = 63.9 years; 55.6%, 19.4% and 25.0% ISUP grade ≤ 2, 3 or ≥4). Among 28 patients who had performed the bone scintigraphy, 6 (21.4%) presented bone metastases, 22 (78.6%) had no bone metastasis. The mean PSA level was 36.7ng/mL in the non-metastatic patients and 97.7 ng/mL in the metastatic patients. The difference in PSA level between the 2 groups was significative (p = 0.041). 63.6% of the non-metastatic cancers versus 16.7% of the metastatic cancers were ISUP grade 2 or less. Inversely, 36.4% of the non-metastatic cancers versus 83.3% of the metastatic cancers were ISUP grade 3 or more. The difference was significative in the ISUP grade 2 or less (p = 0.035), was significative in the ISUP grade group 3 or more (p = 0.035). Metastasis was more likely in prostate cancer patients with PSA equal 30 ng/mL or more and ISUP grade 3 or more (83.3%) than in prostate cancer patients with PSA less than 30 ng/mL and ISUP grade less than 3 (16.7%) [OR = 13.7; CI 95% (1.59; 31.0); p = 0.035]. Conclusion: The scintigraphic detection of bone metastases is low in patients with PSA < 30 ng/mL and ISUP grade < 3. This can be helpful in curative therapy decision making for prostate cancer when nuclear medicine or other metastases detection tools are lacking.
References
[1]
American Cancer Society (2023) Cancer Facts and Figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf
[2]
Sossa, J. and Avakoudjo, D.J.G. (2021) The Prevalence and the Pathological Characteristics of the Prostate Cancer in 138 Consecutive Transrectal Ultrasound-Guided Prostate Biopsies. Journal of Surgery, 7, 558-561.
[3]
Yevi, D.M.I., Hodonou, F., Sossa, J., Amegayibor, O., Akoha, J., et al. (2018) Diagnostic du cancer de la prostate à Cotonou: A propos de 109 cas. Journal de la Recherche Scientifique de l'Université de Lomé, 20, 231-236.
[4]
Amaoko, Y.A., Hammond, E.N., Assasie-Gyimah, A., Laryea, D.O., Ankrah, A. and Amoah, G. (2019) Prostate-Specific Antigen and Risk of Bone Metastases in West Africans with Prostate Cancer. World Journal of Nuclear Medicine, 18, 143-148. https://doi.org/10.4103/wjnm.wjnm_38_18
[5]
Khalid, K.E., Brair, A.I., Elhaj, A.M. and Ali, K.E. (2011) Prostate-Specific Antigen Level and Risk of Bone Metastasis in Sudanese Patients with Prostate Cancer. Saudi Journal of Kidney Diseases and Transplantation, 22, 1041-1043.
[6]
Mottet, N., Cornford, P., et al. (2023) EAU Guidelines on Prostate Cancer 2023. https://uroweb.org/guidelines
[7]
Eastham, J.A., Auffenberg, G.B., Barocas, D.A., Chou, R., Crispino, T., et al. (2022) Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. The Journal of Urology, 208, 10-18. https://doi.org/10.1097/JU.0000000000002757
[8]
Manohar, P.R., Rather, T.A. and Khan, S.H. (2020) Determination of the Optimal Cut-Off Value of Serum Prostate-Specific Antigen in the Prediction of Skeletal Metastases on Technetium-99m Whole-Body Bone Scan by Receiver Operating Characteristic Curve Analysis. World Journal of Nuclear Medicine, 19, 255-259. https://doi.org/10.4103/wjnm.WJNM_77_19
[9]
Lin, Y., Mao, Q., Chen, B., et al. (2017) When to Perform Bone Scintigraphy in Patients with Newly Diagnosed Prostate Cancer: A Retrospective Study. BMC Urology, 17, Article No. 41. https://doi.org/10.1186/s12894-017-0229-z
[10]
McArthur, C., McLaughlin, G. and Meddings, R.N. (2012) Changing the Referral Criteria for Bone Scan in Newly Diagnosed Prostate Cancer Patients. The British Journal of Radiology, 85, 293-472. https://doi.org/10.1259/bjr/79184355
[11]
Qureshi, A.M., Makhdomi, K. and Stones, W. (2017) Prostate-Specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-Control Study. World Journal of Nuclear Medicine, 16, 26-32. https://doi.org/10.4103/1450-1147.181150
[12]
Fendler, W.P., Weber, M., Iravani, A., Hofman, M.S., et al. (2019) Prostate Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Non-Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 25, 7448-7454. https://doi.org/10.1158/1078-0432.CCR-19-1050
[13]
Weinstein, C., Seiden, B., Yeon Pak, S., Karsala, N., et al. (2021) The Concordance between Conventional Computed Tomography and Nuclear Medicine Bone scINtigraphy in the Identification of Prostate Cancer Metastases to Bone. The Journal of Urology, 206, e186. https://doi.org/10.1097/JU.0000000000001984.18
[14]
Nakanishi, K., Tanaka, J., Nakaya, Y., Maeda, N., et al. (2022) Whole-Body MRI: Detecting Bone Metastases from Prostate Cancer. Japanese Journal of Radiology, 40, 229-244. https://doi.org/10.1007/s11604-021-01205-6
[15]
Heindel, W., Gübitz, R., Vieth, V., et al. (2014) The Diagnostic Imaging of Bone Metastases. Deutsches Ärzteblatt International, 111, 741-747. https://doi.org/10.3238/arztebl.2014.0741
[16]
Marangoz, E., Yüksel, D., Yaylali, O., et al. (2022) The Value of Bone Scans to Predict Survival Time in Patients Diagnosed with Prostate Cancer: Single-Center Retrospective Study. Journal of Radiology and Oncology, 6, 4-11. https://doi.org/10.29328/journal.jro.1001040
[17]
Rigaud, J., Tiguert, R., Le Normand, L., Karam, G., et al. (2002) Prognostic Value of Bone Scan in Patients with Metastatic Prostate Cancer Treated Initially with Androgen Deprivation Therapy. The Journal of Urology, 168, 1423-1426. https://doi.org/10.1016/S0022-5347(05)64465-5
